GEN Exclusives

More »

GEN News Highlights

More »
Jun 15, 2010

Asterand to Help Amylin Identify Compounds for the Treatment of Inflammatory Diseases

  • Asterand, through its BioSeek subsidiary, entered a one-year collaboration with Amylin Pharmaceuticals to find drug candidates for a range of inflammatory conditions. BioSeek will apply its BioMAP® predictive human disease models to screen Amylin’s PHORMOL library to discover therapeutic peptides.

    Amylin’s current pipeline comprises drug candidates for metabolic disorders. Various formulations of Byetta are being investigated as a treatment of diabetes; the injectable version is approved in the same indication. Amylin also has an obesity therapy and a molecule for severe lipodystrophy in Phase II and Phase III trials, respectively.

    The deal with Asterand follows similar agreements in recent years between the two companies involving peptide screening and related drug discovery activities. BioMAP Systems are primary cell-based models of human disease biology, designed to replicate the intricate cell and pathway interactions as they are observed in human pharmacology and toxicology.

    Depending on their mechanism of action, drug compounds induce specific patterns of changes in these systems (BioMAP profiles) that can be compared to a large number of reference profiles in the BioMAP Database.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Lab-Grown Vaginas

Which body part do you think will be successfully engineered in the lab next?